 Rigel Pharmaceuticals has four value drivers that could generate substantial revenue growth and have limited downside risk. It appears as if the market has failed to recognize the potential upside. TAVALISSE continues to gain commercial traction in chronic ITP and has the potential to be a market leader in wAIHA and contribute to the battle against COVID-19. 